Glaucoma is the second leading cause of blindness globally, according to the World Health Organisation, affecting over 80 million people. About 2.5 million people worldwide are blind due to glaucoma. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma.
Based on its innovative, proprietary STAR® material, iSTAR Medical is developing a pipeline of devices to treat patients with open angle glaucoma by reducing intraocular pressure (IOP). The STAR material enhances bio-integration and fluid drainage, while conforming to patient anatomy. This has substantial clinical benefits and results in an improved patient experience.
STARfloTM, the company’s proof-of-concept device, is a micro-porous drainage system made of STAR material that increases the eye’s natural uveoscleral outflow. Implantation is achieved through an ab externo surgical procedure that is derived from trabeculectomy, the most common glaucoma filtering surgery.
Leveraging on the positive experience with STARflo, MINIjectTM is an ab interno MIGS device which has been developed in close collaboration with some of the world’s leading scientific and clinical advisors. The device is designed to enhance aqueous humour outflow from the anterior chamber to the suprachoroidal space. Also made of proprietary STAR material, MINIject micro-invasive technology is implanted in a predictable, single-step procedure.